医薬品・バイオテクノロジーにおける資産購入取引：2019-2025年

当レポートでは、医薬品とバイオテクノロジーにおける資産購入取引の動向を調査し、企業が事業、製品、技術、ロイヤリティの資産購入取引を行う方法と理由を詳細に理解し、分析します。

本レポートは、当事者間で発表された資産購入取引の支払条件へのアクセスを提供します。このデータにより、支払い条件やその他の取引条件について有益な洞察が得られます。

本レポートでは、購入可能な主な4種類の資産に焦点を当てています：

• 事業資産
• 製品資産
• ロイヤルティ資産
• 技術資産

主なメリット：

本レポートは、以下の主なメリットを提供します：

• 2019年以降の取引動向を理解できます
• 資産購入取引の閲覧できます
• ベンチマーク分析- 取引の市場価値を特定できます
• 財務- ヘッドライン、契約一時金、マイルストーン、ロイヤルティ率を確認できます
• 企業 (A-Z)、治療領域、技術タイプ別の取引ディレクトリを確認できます
• 主な取引額を確認できます
• もっとも活発な取引メーカーを確認できます
• 各取引の資産と取引条件を特定できます
• 契約文書へのアクセス- 取引構造に関する洞察を得られます
• デューデリジェンス- 提案された取引条件のパートナー企業への適合性を評価できます
• 数百時間の調査時間を節約できます

調査範囲：

• ライフサイエンス業界における資産購入取引の動向
• 資産購入取引構造の概要
• 医薬品、バイオテクノロジー、医療機器、診断薬をカバーする資産購入取引記録のディレクトリ
• 主な資産購入取引
• もっとも活発な資産購入取引メーカー
• 主要な資産購入パートナー情報

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 資産購入取引の動向

• 購入した資産の種類
• 2019年以降の資産購入取引の動向
  • 資産購入取引の動向：年別
  • 資産購入取引：開発段階別
  • 資産購入取引：産業セクター別
  • 資産購入取引：治療領域別
  • 資産購入取引：技術タイプ別
  • 資産購入取引：もっとも活発な企業
• 資産購入提携契約を締結する理由
  • 事業資産
  • 製品資産
  • ロイヤルティ資産
  • 技術資産
• 資産購入取引の将来

第3章 資産購入取引の構造：概要

• 資産購入取引の構造

第4章 主要な資産購入取引

• 上位資産購入取引：金額別

第5章 もっとも活発な資産購入取引メーカー上位25社

• もっとも活発な資産購入取引メーカー上位25社

第6章 契約ディレクトリを含む資産購入取引

• 2019年から2025年までの契約・資産購入取引
• 取引ディレクトリ
• 取引ディレクトリ- 資産購入取引：企業別 (A-Z)
• 取引ディレクトリ- 資産購入取引：治療領域別
• 取引ディレクトリ- 資産購入取引：技術タイプ別
• Biopharma Research Ltdについて
• 現在の提携
• 現在の契約
• Current Partneringからの最近のレポートタイトル

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

• Business assets
• Product assets
• Royalty assets
• Technology assets
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of asset purchase deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
• Chapter 3 provides an overview of the structure of asset purchase deals.
• Chapter 4 provides a review of the leading asset purchase deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
• Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
• The deal directory includes a comprehensive listing of all asset purchase deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
• The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2019.
• In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.

Key benefits

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse asset purchase deals
• Benchmark analysis - identify market value of transactions
• Financials - headline, upfront, milestone, royalty rates
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Asset Purchase Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Asset Purchase Deals in Pharmaceuticals and Biotechnology includes:

• Trends in asset purchase dealmaking in the life sciences industry
• Overview of asset purchase deal structure
• Directory of asset purchase deal records covering pharmaceuticals, biotechnology, medical devices and diagnostics
• The leading asset purchase deals by value
• Most active asset purchase dealmakers
• The leading asset purchase partnering resources

In Asset Purchase Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via hyperlink to an online version of the actual deal record, providing easy access to each contract document where available.
• Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for asset purchase deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

• 2.1. Introduction
• 2.2. Types of assets purchased
• 2.3. Trends in asset purchase deals since 2019
  • 2.3.1. Asset purchase dealmaking by year, 2019-2025
  • 2.3.2. Asset purchase dealmaking by phase of development, 2019-2025
  • 2.3.3. Asset purchase dealmaking by industry sector, 2019-2025
  • 2.3.4. Asset purchase dealmaking by therapy area, 2019-2025
  • 2.3.5. Asset purchase dealmaking by technology type, 2019-2025
  • 2.3.6. Asset purchase dealmaking by most active company, 2019-2025
• 2.4. Reasons for entering into asset purchase partnering deals
  • 2.4.1. Business assets
  • 2.4.2. Product assets
  • 2.4.3. Royalty assets
  • 2.4.4. Technology assets
• 2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

• 3.1. Introduction
• 3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

• 4.1. Introduction
• 4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

• 6.1. Introduction
• 6.2. Asset purchase deals with contracts 2019-2025
• Deal directory
• Deal directory - Asset purchase dealmaking by companies A-Z
• Deal directory - Asset purchase dealmaking by therapy area
• Deal directory - Asset purchase dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of assets purchased
• Figure 2: Trends in asset purchase deal announcements, 2019-2025
• Figure 3: Asset purchase deals signed at each phase of development, 2019-2025
• Figure 4: Asset purchase deals by industry sector, 2019-2025
• Figure 5: Asset purchase deals by therapy area, 2019-2025
• Figure 6: Asset purchase deals by technology type, 2019-2025
• Figure 7: Top 25 most active asset purchase dealmakers, 2019-2025
• Figure 8: Top asset purchase deals by value, 2019-2025
• Figure 9: Most active asset purchase dealmakers, 2019-2025